Fibroblast growth factor (
FGF) receptor 2 (FGFR-2) polymorphisms have been associated with an increase in
estrogen receptor and
progesterone receptor (PR)-positive
breast cancer risk; however, a clear mechanistic association between FGFR-2 and
steroid hormone receptors remains elusive. In previous works, we have shown a cross talk between
FGF2 and
progestins in mouse mammary
carcinomas. To investigate the mechanisms underlying these interactions and to validate our findings in a human setting, we have used T47D human
breast cancer cells and human
cancer tissue samples. We showed that
medroxyprogesterone acetate (MPA) and
FGF2 induced cell proliferation and activation of ERK, AKT, and STAT5 in T47D and in murine C4-HI cells. Nuclear interaction between PR, FGFR-2, and STAT5 after MPA and
FGF2 treatment was also showed by confocal microscopy and immunoprecipitation. This effect was associated with increased transcription of PRE and/or GAS reporter genes, and of PR/STAT5-regulated genes and
proteins. Two antiprogestins and the FGFR inhibitor
PD173074, specifically blocked the effects induced by
FGF2 or MPA respectively. The presence of PR/FGFR-2/STAT5 complexes bound to the PRE probe was corroborated by using NoShift transcription and
chromatin immunoprecipitation of the MYC promoter. Additionally, we showed that T47D cells stably transfected with constitutively active FGFR-2 gave rise to invasive
carcinomas when transplanted into NOD/SCID mice. Nuclear colocalization between PR and FGFR-2/STAT5 was also observed in human
breast cancer tissues. This study represents the first demonstration of a nuclear interaction between FGFR-2 and STAT5, as PR coactivators at the
DNA progesterone responsive elements, suggesting that FGFRs are valid therapeutic targets for human
breast cancer treatment.